Northwire Canada EditionMonday, July 13, 2026
Sign inSubscribe
Northwire
⌕
S 0.160 +3.2% OMI 0.315 +0.0% BMM 4.02 +5.8% CGD 0.630 +10.5% OCG 0.275 −1.8% CAMB 0.990 −1.0% HMR 0.600 −3.2% GOFL 0.025 +0.0% SIG 1.01 −1.9% SGQ 0.300 +0.0% AMCO 0.220 −12.0% TRS 0.055 +0.0% RRI 0.265 +0.0% GAL 0.390 −2.5% LIB 0.800 −12.1% SMY 0.290 +23.4% S 0.160 +3.2% OMI 0.315 +0.0% BMM 4.02 +5.8% CGD 0.630 +10.5% OCG 0.275 −1.8% CAMB 0.990 −1.0% HMR 0.600 −3.2% GOFL 0.025 +0.0% SIG 1.01 −1.9% SGQ 0.300 +0.0% AMCO 0.220 −12.0% TRS 0.055 +0.0% RRI 0.265 +0.0% GAL 0.390 −2.5% LIB 0.800 −12.1% SMY 0.290 +23.4%
M&A / Property Routine +

TempraMed Signs LOI for Distribution Agreement in Panama, Expanding Central American Exposure

TempraMed’s Panama LOI Adds Another Geographic Checkbox as Stock Tests Multi-Month Lows Amid Unproven Commercial Traction

By The Northwire Desk — AI Analysis Mar 30, 2026 · 07:01 VIVI · 0.76 TempraMed Technologies Ltd.
Executive Summary
  • TempraMed signed a non-binding Letter of Intent with TEM Consulting International S.A. to distribute its VIVI product portfolio across Panama
  • The LOI targets a 90-day timeline to execute a definitive distribution agreement, focusing initially on urban, higher-income private-pay patients
  • TEM Consulting provides access to Panama’s hospital, clinic, and pharmacy networks, marking TempraMed’s first formal entry into Central America
  • The announcement follows a consistent pattern of geographic expansion, including recent distribution agreements in Israel, Turkey, South Korea, and the Benelux region
  • Management frames the partnership as a strategic step to accelerate product adoption in a market with rising diabetes prevalence and high out-of-pocket costs for GLP-1 and insulin therapies
Material Impact
  • The Panama LOI is incremental and aligns with the company’s established playbook of signing regional distribution agreements
  • As a non-binding LOI, it carries no immediate financial impact, revenue recognition, or guaranteed volume commitments
  • The market has already digested multiple similar announcements over the past six months without sustained price appreciation, indicating investor skepticism regarding conversion from LOI to actual sales
  • Given the stock’s decline from $1.30 to $0.66 despite continuous PR flow, this release does not alter the fundamental risk profile or near-term cash trajectory
  • The news is categorized as Routine - Positive: strategically consistent but lacking near-term financial materiality or unexpected catalysts
VIVI · Price
Company Overview
  • TempraMed develops passive, battery-free temperature-control devices for injectable medications, targeting insulin, GLP-1 therapies, biologics, and emergency injectables
  • Flagship products include VIVI Cap, VIVI Cap Smart (digital tracking/subscription model), VIVI Epi, VIVI Med (vial/biologic format), and the upcoming VIVI Box multi-medication storage platform
  • The company is transitioning from a direct-to-consumer e-commerce model to B2B pharmacy, distributor, and institutional healthcare channels
  • Intellectual property portfolio includes multiple international patents covering thermal insulation, smart monitoring, and power-interruption protection technologies
  • Management emphasizes a path to revenue and cash-flow positivity through institutional partnerships, payor reimbursement, and recurring digital subscription revenue
Read the original news release →

More from TempraMed Technologies Ltd.

Jun 30, 2026 · 03:06

TempraMed Expands Strategic Partnership with McKesson Medical-Surgical to Accelerate North American Growth and Launch Full Portfolio Across B2B Channels

M&A / Property Jun 26, 2026 · 16:11

Pioneering passive thermal protection for temperature-sensitive injectables amid aggressive global distribution expansion.

M&A / Property Jun 04, 2026 · 07:01

TempraMed Signs Agreement for Exclusive Distribution Partnership in Brazil, One of the Largest Diabetes and Biologics Markets Globally

Other May 22, 2026 · 11:58

TempraMed Technologies Ltd.

Other May 14, 2026 · 03:01

Indian patent adds IP depth but revenue-sharing financing signals cash crunch

Financings Apr 07, 2026 · 07:01

Brazilian patent bolsters TempraMed’s IP moat ahead of VIVI Box launch.

M&A / Property